Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $38.7700 (2.46%) ($38.7700 - $38.7700) on Thu. Jun. 24, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.92% (three month average) | RSI | 73 | Latest Price | $38.7700(2.46%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.6% a day on average for past five trading days. | Weekly Trend | TGTX advances 1.2% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(68%) ARKG(63%) ARKK(59%) IBB(59%) IWO(59%) | Factors Impacting TGTX price | TGTX will decline at least -1.46% in a week (0% probabilities). VIXM(-45%) VXX(-38%) UUP(-18%) UNG(-3%) TLT(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.46% (StdDev 2.92%) | Hourly BBV | 1.6 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $37.85(2.43%) | 10 Day Moving Average | $37.73(2.76%) | 20 Day Moving Average | $36.76(5.47%) | To recent high | -20.4% | To recent low | 19.5% | Market Cap | $4.91b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |